Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study — Peter Brønnum Nielsen (2021) | RDL Network
Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study
Article 2021 en
Authors
PN
Peter Brønnum Nielsen
MS
Mette Søgaard
MJ
Martin Jensen
Abstract
1 min read
Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for Danish (mainly Caucasian) patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality.
Line Melgaard, Thure Filskov Overvad, Martin Jensen, Thomas Decker Christensen, Professor Gregory Lip, Torben Bjerregaard Larsen, Peter Brønnum Nielsen
Hee Tae Yu, Pil‐Sung Yang, Tae‐Hoon Kim, Eunsun Jang, Daehoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Hui‐Nam Pak, Moon‐Hyoung Lee, Professor Gregory Lip, Boyoung Joung
Discussion(0)
No comments yet. Be the first to comment.